---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-238557"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T11:55:34.583177+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences receives Nasdaq bid price deficiency notice; 180 days to comply

## Summary
- Received Nasdaq notice on Sept 14, 2023 for bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days, until March 12, 2024, to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.
- No immediate impact on listing or trading; may be eligible for additional 180-day compliance period if needed.
- Intends to monitor bid price and consider options, including potential reverse stock split to cure deficiency.

## SEC filing metadata
- accession: 0001193125-23-238557
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312523238557/0001193125-23-238557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312523238557/d476127d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-238557
- JSON: https://secwatch.observer/filing/0001193125-23-238557.json
- Plain text: https://secwatch.observer/filing/0001193125-23-238557.txt

## Key facts
- Listing & Compliance Notices
  Forte Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: September 14, 2023, Forte Biosciences, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312523238557/0001193125-23-238557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.